RIGHT VENTRICULAR FUNCTION AS ASSESSED BY TRICUSPID ANNULAR PLANE SYSTOLIC EXCURSION IN PATIENTS UNDERGOING TRANSCATHETER TRICUSPID VALVE REPLACEMENT WITH EVOQUE VALVE
Recommended Citation
Abdelhai OS, Villablanca PA, Rangavajla G, Frisoli TM, O’Neill BP, Lee JC, Zweig B, Fram G, Nguyen F. RIGHT VENTRICULAR FUNCTION AS ASSESSED BY TRICUSPID ANNULAR PLANE SYSTOLIC EXCURSION IN PATIENTS UNDERGOING TRANSCATHETER TRICUSPID VALVE REPLACEMENT WITH EVOQUE VALVE. J Am Coll Cardiol 2025; 85(12):933.
Document Type
Conference Proceeding
Publication Date
4-1-2025
Publication Title
J Am Coll Cardiol
Keywords
adult, clinical article, conference abstract, conservative treatment, controlled study, echocardiograph, echocardiography, female, follow up, heart failure, heart right ventricle function, hospital readmission, hospitalization, human, male, retrospective study, tricuspid annular plane systolic excursion, tricuspid valve prosthesis, tricuspid valve regurgitation, tricuspid valve replacement
Abstract
Background: Transcatheter tricuspid valve replacement (TTVR) with the Evoque valve represents a new commercially available nonsurgical therapy for severe tricuspid regurgitation (TR) in the US. Limited data has been published on the impact of this intervention on right ventricular function. Methods We performed a retrospective review of patients that underwent commercial TTVR with Evoque valve at our institution between February and July 2024 (n=40), assessing tricuspid annular plane systolic excursion (TAPSE) as reported by interpreting physician on transthoracic echocardiogram before the procedure, 1-day post-procedure and 30-days post-procedure. Results The median TAPSE reported pre-procedure was 15.3 mm (IQR 14-19) with reductions seen at 1 day [13.8 mm (IQR 11-16, p=0.03)] and 30 days [12.1 mm (IQR 10-16; p=0.01)]. Despite two deaths and five heart failure (HF) readmissions in this cohort at the 30day follow-up, no statistical correlation was found between TAPSE reduction and mortality or HF readmissions (p=0.62, CI=0.24-2.4). Conclusion The use of TAPSE to assess right ventricular function post TTVR with Evoque has yet to be validated, and further investigation on how to best assess right ventricular function post TTVR is needed. We investigated a cohort of patients in whom TAPSE has been reported and noted a post-procedural reduction in median TAPSE at 30 days that was not associated with instances of hospitalization or mortality. [Formula presented]
Volume
85
Issue
12
First Page
933
